Organisation paid for research Program year 2025 Source: CMS Open Payments

Sarah Cannon Development Innovation

Neither a doctor nor a teaching hospital

Research payments

$3,890,150

50 payments

Through program year 2025, Sarah Cannon Development Innovation is reported as receiving $3,890,150 in research payments, across 50 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2025	Research	$3,686,332	44
2023	Research	$184,124	1
2022	Research	$2,275	1
2019	Research	$17,420	4

Breakdown

Who paid Research payments · program years 2019–2025

Janssen Research & Development, LLC $3,686,332 44 payments
GlaxoSmithKline, LLC. $186,399 2 payments
Astellas Pharma Global Development $17,420 4 payments

Studies the money was for Research payments · program years 2019–2025

A Study of Outpatient Administration of Teclistamab, a BCMA-targeting Bispecific, in Multiple Myeloma Patients $3,686,332 44 payments
A Phase II, Open-Label, Multi-Center Study of Belantamab Mafodotin, Bo $184,124 1 payment
Enzalutamide plus Everolimus in Men with Metastatic Castrate-Resistant Prostate Cancer and Previous Treatment with Docetaxel A Phase I Study with a Maximum Tolerated Dose Expansion Cohort $17,420 4 payments
Phase 2, Multi-Arm Study of Niraparib Administered Alone and in Combin $2,275 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.